$131 Million is the total value of ACUTA CAPITAL PARTNERS, LLC's 21 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 58.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IOVA | Buy | IOVANCE BIOTHERAPEUTICS INC | $26,720,000 | +6.9% | 3,019,201 | +35.8% | 20.38% | +128.5% |
| ASMB | Sell | ASSEMBLY BIOSCIENCES INC | $16,252,000 | -52.9% | 718,500 | -22.7% | 12.40% | +0.6% |
| KDMN | Buy | KADMON HLDGS INC | $15,679,000 | -36.5% | 7,538,000 | +1.9% | 11.96% | +35.7% |
| CASM | CAS MED SYS INC | $8,422,000 | -29.8% | 5,263,508 | 0.0% | 6.42% | +50.0% | |
| XBI | SPDR SERIES TRUSTput | $7,175,000 | -25.2% | 100,000 | 0.0% | 5.47% | +60.0% | |
| BHVN | Buy | BIOHAVEN PHARMACTL HLDG CO L | $6,934,000 | +39.4% | 187,500 | +41.5% | 5.29% | +197.9% |
| AMRN | Buy | AMARIN CORP PLCspons adr new | $5,954,000 | +415.5% | 437,500 | +516.2% | 4.54% | +1002.2% |
| IMMU | Sell | IMMUNOMEDICS INC | $5,708,000 | -86.7% | 400,000 | -80.5% | 4.35% | -71.5% |
| IMMU | New | IMMUNOMEDICS INCput | $5,708,000 | – | 400,000 | +100.0% | 4.35% | – |
| VCYT | Sell | VERACYTE INC | $5,567,000 | -46.6% | 442,500 | -59.5% | 4.25% | +14.1% |
| IRIX | Sell | IRIDEX CORP | $5,520,000 | -55.4% | 1,174,500 | -39.7% | 4.21% | -4.6% |
| ARGX | Sell | ARGENX SEsponsored adr | $5,092,000 | -36.1% | 53,000 | -49.5% | 3.88% | +36.8% |
| KALV | Buy | KALVISTA PHARMACEUTICALS INC | $3,417,000 | +19.9% | 173,000 | +34.3% | 2.61% | +156.5% |
| XENE | Buy | XENON PHARMACEUTICALS INC | $3,392,000 | -46.7% | 537,500 | +11.4% | 2.59% | +13.9% |
| ACER | Buy | ACER THERAPEUTICS INC | $2,877,000 | -14.6% | 143,000 | +30.9% | 2.19% | +82.5% |
| CEMI | Sell | CHEMBIO DIAGNOSTICS INC | $2,191,000 | -89.7% | 387,167 | -80.9% | 1.67% | -78.0% |
| BHVN | BIOHAVEN PHARMACTL HLDG CO Lcall | $1,990,000 | -1.5% | 53,800 | 0.0% | 1.52% | +110.5% | |
| VRAY | VIEWRAY INC | $1,891,000 | -35.2% | 311,500 | 0.0% | 1.44% | +38.7% | |
| STRO | New | SUTRO BIOPHARMA INC | $410,000 | – | 45,500 | +100.0% | 0.31% | – |
| BCRX | New | BIOCRYST PHARMACEUTICALS | $202,000 | – | 25,000 | +100.0% | 0.15% | – |
| OTLK | New | OUTLOOK THERAPEUTICS INC | $15,000 | – | 29,082 | +100.0% | 0.01% | – |
| ONS | Exit | ONCOBIOLOGICS INC | $0 | – | -29,082 | -100.0% | -0.01% | – |
| GTXI | Exit | GTX INC DELput | $0 | – | -100,000 | -100.0% | -0.06% | – |
| ALIM | Exit | ALIMERA SCIENCES INC | $0 | – | -267,500 | -100.0% | -0.09% | – |
| AMAG | Exit | AMAG PHARMACEUTICALS INCput | $0 | – | -40,000 | -100.0% | -0.28% | – |
| CHRS | Exit | COHERUS BIOSCIENCES INCcall | $0 | – | -50,000 | -100.0% | -0.29% | – |
| ECYT | Exit | ENDOCYTE INC | $0 | – | -92,000 | -100.0% | -0.58% | – |
| MGTA | Exit | MAGENTA THERAPEUTICS INC | $0 | – | -170,000 | -100.0% | -0.73% | – |
| ARWR | Exit | ARROWHEAD PHARMACEUTICALS INcall | $0 | – | -200,000 | -100.0% | -1.37% | – |
| ASND | Exit | ASCENDIS PHARMA A Ssponsored adr | $0 | – | -71,500 | -100.0% | -1.81% | – |
| ASMB | Exit | ASSEMBLY BIOSCIENCES INCcall | $0 | – | -147,500 | -100.0% | -1.95% | – |
| CHRS | Exit | COHERUS BIOSCIENCES INC | $0 | – | -353,500 | -100.0% | -2.08% | – |
| MDGL | Exit | MADRIGAL PHARMACEUTICALS INC | $0 | – | -33,000 | -100.0% | -2.52% | – |
| REGN | Exit | REGENERON PHARMACEUTICALSput | $0 | – | -20,000 | -100.0% | -2.88% | – |
| ARWR | Exit | ARROWHEAD PHARMACEUTICALS IN | $0 | – | -775,000 | -100.0% | -5.30% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS INC | 24 | Q1 2023 | 21.2% |
| IRIDEX CORP | 20 | Q3 2019 | 8.1% |
| ARROWHEAD PHARMACEUTICALS INC | 20 | Q2 2023 | 7.9% |
| IMMUNOMEDICS INC | 19 | Q3 2020 | 20.6% |
| VERACYTE INC | 19 | Q3 2019 | 10.1% |
| ASCENDIS PHARMA A S | 18 | Q2 2020 | 7.2% |
| XENON PHARMACEUTICALS INC | 18 | Q3 2022 | 4.6% |
| CAS MED SYS PAR $0.004 | 18 | Q1 2019 | 6.4% |
| APELLIS PHARMACEUTICALS INC | 17 | Q3 2023 | 18.4% |
| KURA ONCOLOGY INC. COMMON STOCK | 17 | Q3 2023 | 8.1% |
View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| BCLS Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| Jiya Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Aadi Bioscience, Inc. | September 07, 2021 | 1,529,402 | 7.2% |
| Kadmon Holdings, Inc. | February 14, 2020 | 7,373,333 | 4.6% |
| IRIDEX CORPSold out | November 13, 2019 | 0 | 0.0% |
| ASSEMBLY BIOSCIENCES, INC. | February 14, 2019 | 718,500 | 2.8% |
| CAS MEDICAL SYSTEMS INC | February 14, 2019 | 5,263,508 | 18.2% |
View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View ACUTA CAPITAL PARTNERS, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.